A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
BACKGROUND
It has been proposed that treatments for irritable bowel syndrome with constipation (IBS-C) should provide rapid symptomatic relief, be intermittent, and effective upon repeated use.


OBJECTIVE
To evaluate the efficacy and safety of tegaserod on IBS symptoms, and its impact on quality of life and health economic measures.


METHODS
Women (> or = 18 years of age) with IBS-C according to the Rome II criteria.


METHODS
Prospective, double blind, placebo controlled, randomised trial. Women with IBS-C either received tegaserod 6 mg twice daily or placebo for one month. Patients with at least a partial response entered a treatment free interval. Upon symptom recurrence, tegaserod treated patients were re-randomised to tegaserod or placebo for an additional month. Primary efficacy variables were response (overall IBS symptoms and abdominal discomfort/pain) to first and repeated treatment. Analysis was by intention to treat.


RESULTS
2660 patients and 1191 patients were randomised for first and repeated treatment respectively. Tegaserod was superior to placebo for each primary efficacy variable (first treatment: 33.7% v 24.2% responders respectively for relief of IBS symptoms and 31.3% v 22.1% for relief of abdominal discomfort/pain; repeated treatment: 44.9% v 28.7%, and 42.4% v 27.1%, all p < 0.0001). Tegaserod was superior to placebo for every secondary efficacy variable (relief of abdominal discomfort/pain, bloating and constipation; stool frequency and consistency). A response to tegaserod was observed within the first treatment week. Tegaserod produced greater satisfaction, work productivity, and improved quality of life than placebo (p < 0.05).


CONCLUSIONS
Tegaserod provides rapid and sustained relief of IBS-C symptoms both during first and repeated treatment.
Tack
J
J
Department of Gastroenterology, Centre for Gastroenterological Research, University of Leuven, Leuven, Belgium. Jan.Tack@med.kuleuven.ac.be
Müller-Lissner
S
S
Bytzer
P
P
Corinaldesi
R
R
Chang
L
L
Viegas
A
A
Schnekenbuehl
S
S
Dunger-Baldauf
C
C
Rueegg
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D003248:Constipation / Q000188:drug therapy* / Q000534:rehabilitation; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004526:Efficiency; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000534:rehabilitation; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D005765:Gastrointestinal Agents; D007211:Indoles; D017366:Serotonin Receptor Agonists; C105050:tegaserod